Endometrial hyperplasia can also be suggested by ultrasonographic findings (ie, endometrial thickness >5 mm), which are useful for excluding hyperplasia and cancer of the endometrium in postmenopausal women
The FSH rise precedes the LH rise; FSH is the diagnostic marker for ovarian failure, while LH is not necessary to make the diagnosis
FSH levels are higher than luteinizing hormone (LH) levels, and both rise to even higher values than those seen in the surge during the menstrual cycle
No secretory changes are observed after menopause, because no ovulation occurs and therefore no corpus luteum forms to produce progesterone
Endometrial hyperplasia is a sign of hyperstimulation by estrogen from either endogenous sources or replacement therapy and may be a precursor of endometrial cancer
No specific changes in thyroid function related to menopause have been found
An increase in serum follicle-stimulating hormone (FSH) and decreases in estradiol and inhibin are the major endocrine changes that occur during the transition to menopause
Endometrial biopsy can show a range of endometrial appearances, from mildly proliferate to atrophic
The large cyclical variation of estradiol and estrone observed during the menstrual years ceases, and fluctuation in levels is small and inconsequential, with the mean value being considerably lower
